Lilly
  • Prescribing Information
  • Patient Prescribing Information
Menu closed
Lilly
  • Prescribing Information
  • Patient Prescribing Information
  • For Patients
    • CYRAMZA® (ramucirumab)
    • ERBITUX® (cetuximab)
    • Jaypirca® (pirtobrutinib)
    • Retevmo® (selpercatinib)
    • Verzenio Continuous Care™ Support Program
  • For Healthcare Providers
    • Support and Resources
  • Contact Us
Globe Loading... Reveal available languages

Lilly Oncology Support Center Sitemap

For Patients

For Patients Home

  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Jaypirca® (pirtobrutinib)
  • Retevmo® (selpercatinib)
  • Verzenio Continuous Care™ Support Program

For Healthcare Providers

For Healthcare Providers Home

  • CYRAMZA® (ramucirumab)
  • ERBITUX® (cetuximab)
  • Jaypirca® (pirtobrutinib)
  • Retevmo® (selpercatinib)
  • Verzenio® (abemaciclib)
  • Support and Resources

Contact Us

Terms of Use
Privacy Statement
Consumer Health Privacy Notice
Accessibility Statement
Sitemap

To speak to customer support:
Call 1-866-472-8663
Monday - Friday, 8am — 10pm ET

This site is intended for US residents ages 18 and over.

PP-OC-US-0369 12/2023 ©Lilly USA, LLC 2023. All rights reserved.

CYRAMZA®, ERBITUX®, Retevmo®, Verzenio®, and Jaypirca® are registered trademarks and Verzenio Continuous Care™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Other product/company names mentioned herein are the property of their respective owners.

Your Privacy Choices

Cookie Settings

Terms of UsePrivacy StatementConsumer Health Privacy NoticeAccessibility StatementSitemap
Lilly